• NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ({{d.PerChg}}%)
Market | Equity | Daily Market Tracker | IPO Synopsis
Gland Pharma Ltd
Registered Office:
Sy No 143-148 150&151 Nr Gandi,X Roads D P Pally Dundigal,
Hyderabad - 500043,
Telangana, India.
Initial public offer of 43196968 equity shares of face value of Re. 1 each ("equity shares") of Gland Pharma Limited ("Company" or "Issuer") for cash at a price of (Rs)1500 Per equity share (including a share premium of (Rs)1499 per equity share) aggregating (Rs)6479.55 crores (The "Offer") comprising a fresh issue of 8,333,333 equity shares aggregating up to (Rs) 1250 crores on (The "fresh issue") and an offer for sale of 34,863,635 equity shares, including 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd ("promoter selling shareholder") and 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Limited, 3,573,014 equity shares By Empower Discretionary Trust, and 1,874,500 equity shares by Nilay Discretionary Trust (collectively, the "other selling shareholders" and collectively With the promoter selling shareholder are referred to as the "selling shareholders", and such equity shares, the "offered shares") aggregating up to (Rs) 5229.55 crores (the "offer for sale"). The offer shall constitute 26.46% of the post-offer paid-up equity share capital of the company. The face value of Equity shares is Re.1 each. The offer price is (Rs)1500 per equity share and is 1500 times the face value of the Equity Shares. The Anchor Investor Offer Price is (Rs)1500 per Equity Share.
Money Payable On
Opens On
Closes On
Minimum Application for shares in Nos : 10     Further Multiples of : 10
Lead Managers to the Issue
Project Cost
Citigroup Global Markets India Pvt Ltd
Project Financed
Post Issue
Issue Price
Funding incremental working capital requirements of the company
Funding capital expenditure requirements of the company
General corporate purposes
Promoted By
Fosun Pharma Indust. Pte. Ltd
Shanghai Fosun Pharma. Group
Listing At
Registrar to the Issue
Link Intime India Pvt Ltd
DB (International) Stock Brokers Limited: SEBI Reg. No.-INZ000179035 / CDSL : IN-DP-CDSL-266-2004 MCX-SX:INE 260643233/21500(CD)
Daga Commodities Private Limited: SEBI Reg. No. INZ000028833
Investor Grievances Email ID: compliance@dbonline.in & investors@dbonline.in
Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and content powered by C-MOTS Infotech( ISO 9001:2015 certified )
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries